

## RESEARCH ARTICLE

# Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children

Valeria Pegoraro<sup>1</sup>, Ducciocompet Urbinati<sup>1</sup>, Gerard H. A. Visser<sup>2</sup>, Gian Carlo Di Renzo<sup>3,4</sup>, Alvin Zipursky<sup>5</sup>, Brie A. Stotler<sup>6</sup>, Steven L. Spitalnik<sup>6\*</sup>

**1** IQVIA Solutions Italy S.r.l., Milan, Italy, **2** Departments of Obstetrics, University Medical Center, Utrecht, the Netherlands, **3** Department of Obstetrics and Gynecology, University of Perugia, Perugia, Italy, **4** Department of Obstetrics and Gynecology, I.M. Sechenov First State University of Moscow, Moscow, Russia, **5** Hospital for Sick Children, Toronto, Ontario, Canada, **6** Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America

\* [ss2479@cumc.columbia.edu](mailto:ss2479@cumc.columbia.edu)



## OPEN ACCESS

**Citation:** Pegoraro V, Urbinati D, Visser GHA, Di Renzo GC, Zipursky A, Stotler BA, et al. (2020) Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children. PLoS ONE 15(7): e0235807. <https://doi.org/10.1371/journal.pone.0235807>

**Editor:** Ju Lee Oei, University of New South Wales, AUSTRALIA

**Received:** June 24, 2019

**Accepted:** June 24, 2020

**Published:** July 20, 2020

**Copyright:** © 2020 Pegoraro et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Relevant data are within the paper and its Supporting Information files. All of the data that support the findings of this study are publicly available with the exception of the IQVIA Multinational Integrated Data Analysis System (MIDAS); the latter is the property of IQVIA and, as such, restrictions apply to the availability of this information, which was used under license for the current study, and is not publicly available. MIDAS data are of IQVIA property. Authors VP and DU, who are IQVIA employees, can access the data

## Abstract

In the mid-20<sup>th</sup> century, Hemolytic Disease of the Fetus and Newborn, caused by maternal alloimmunization to the Rh(D) blood group antigen expressed by fetal red blood cells (i.e., “Rh disease”), was a major cause of fetal and neonatal morbidity and mortality. However, with the regulatory approval, in 1968, of IgG anti-Rh(D) immunoprophylaxis to prevent maternal sensitization, the prospect of eradicating Rh disease was at hand. Indeed, the combination of antenatal and post-partum immunoprophylaxis is ~99% effective at preventing maternal sensitization to Rh(D). To investigate global compliance with this therapeutic intervention, we used an epidemiological approach to estimate the current annual number of pregnancies worldwide involving an Rh(D)-negative mother and an Rh(D)-positive fetus. The annual number of doses of anti-Rh(D) IgG required for successful immunoprophylaxis for these cases was then calculated and compared with an estimate of the annual number of doses of anti-Rh(D) produced and provided worldwide. Our results suggest that ~50% of the women around the world who require this type of immunoprophylaxis do not receive it, presumably due to a lack of awareness, availability, and/or affordability, thereby putting hundreds of thousands of fetuses and neonates at risk for Rh disease each year. The global failure to provide this generally acknowledged standard-of-care to prevent Rh disease, even 50 years after its availability, contributes to an enormous, continuing burden of fetal and neonatal disease and provides a critically important challenge to the international health care system.

with no restrictions and without the need of special access privileges. Analyses involving MIDAS data have been performed by VP. VP and DU were the only authors who have access to the data without restrictions. The MIDAS data are available from the authors upon reasonable request and with permission of IQVIA or from: Franca Heiman, HEOR Engagement Manager, IQVIA, RWS, Italy. E-mail address: [franca.heiman@iqvia.com](mailto:franca.heiman@iqvia.com).

**Funding:** This study was sponsored by an unrestricted grant from Kedrion S.p.A. (<https://www.kedrion.com>) to IQVIA Solutions Italy S.r.l., which then provided support in the form of salaries for Valeria Pegoraro and Duccio Urbinati. Nonetheless, Kedrion S.p.A. had no role in study design, data collection and analysis, the decision to submit a manuscript for publication, or the preparation or editing of the manuscript. The funder provided support in the form of salaries for authors Valeria Pegoraro and Duccio Urbinati, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

**Competing interests:** Dr. Spitalnik has read the journal's policy and the authors of this manuscript have the following competing interests: he is a member of the Scientific Advisory Board of Hemanext, Inc. and a consultant for Tioma, Inc. However, neither of these competing interests are relevant to the content of the submitted manuscript. Valeria Pegoraro and Duccio Urbinati are employees of IQVIA Solutions Italy S.r.l. However, none of these competing interests are relevant to the content of the submitted manuscript. The other authors have declared that no competing interests exist.

## Introduction

Hemolytic Disease of the Fetus and Newborn (HDFN) is caused by maternal alloimmunization to blood group antigens expressed by fetal red blood cells. In severe cases, HDFN induces fetal anemia with increased risks of fetal death, severe neonatal hyperbilirubinemia, and kernicterus [1–3]. Before 1945, ~50% of all fetuses with hemolytic diseases of various etiologies died of kernicterus or hydrops fetalis [4]. Most severe cases of HDFN were attributed to Rh(D) incompatibility between an Rh(D)-negative woman and her Rh(D)-positive fetus, with Rh(D) alloimmunization having occurred during a previous pregnancy [2, 3]. In the 1960s, studies in the United States and in Great Britain determined that passive immunization of Rh(D)-negative mothers with IgG anti-Rh(D), soon after parturition, could protect women from sensitization against Rh(D)-positive red blood cells [5]. This then led to regulatory approval and licensure of IgG anti-Rh(D) preparations for routine post-partum prophylaxis in 1968, more than 50 years ago.

However, in 1977 it was demonstrated that, despite adequate post-natal prophylaxis, ~10% of Rh(D)-negative women continued to develop anti-Rh(D) antibodies, presumably due to small, transplacental, fetal-maternal hemorrhages during pregnancy [6]. To address this issue, antenatal administration of IgG anti-Rh(D) preparations was instituted, which virtually abolished this phenomenon, when combined with standard post-partum prophylaxis [1, 2, 7–9]. Therefore, most current guidelines, prepared by various associations of healthcare professionals involved in preventing and managing HDFN, including obstetricians and gynecologists, pediatricians and neonatologists, hematologists, and specialists in transfusion medicine, recommend that immunoprophylaxis with IgG anti-Rh(D) be given to every non-sensitized Rh(D)-negative woman, as follows: (1) at 28 weeks of gestation during each pregnancy, (2) immediately after delivery of every Rh(D)-positive neonate, and (3) in the context of any other event that could expose her to the Rh(D) antigen (e.g., abortion, miscarriage, abdominal trauma) [3, 4, 7–10]. The only settings in which antenatal anti-D IgG administration is not necessary is when the father is also Rh(D)-negative or if the fetus is successfully typed for Rh(D) status by antenatal cell-free DNA testing using maternal plasma [1, 2].

What has been described up to now is undoubtedly a success story and a great achievement of science and medicine. However, a review of the literature revealed very few publications describing the prevalence of Rh(D) disease in low income countries, where it is not generally considered to be a major problem, presumably due to a lower prevalence of the Rh(D)-negative blood type than in high income countries and an absence of data collection and disease monitoring for this disorder [11–13]. In addition, to our knowledge, no previous studies attempted to demonstrate that both antenatal and post-partum prophylaxis are effectively and consistently used in high income countries. Therefore, the main objective of the present study is to attempt to quantify the worldwide “gap” between the annual number of doses of IgG anti-Rh(D) that should theoretically be administered to minimize the risk of Rh(D) sensitization, and the annual number of doses of IgG anti-Rh(D) that are actually administered.

## Methods

### Parameters and data sources

The parameters needed to calculate the number of doses of IgG anti-Rh(D) that should be administered annually to minimize maternal Rh(D) sensitization are: (1) the number of births per year in each country and (2) the prevalence of the Rh(D)-negative phenotype in those countries.

For most countries, the number of births per year, updated in 2015, was provided by UNICEF [14], which was demonstrated to be a reliable data source in a prior study [13]. For countries for which this information was not available from UNICEF, the number of births per year was calculated based on the number of inhabitants and the birth rates reported in the World Factbook of the Central Intelligence Agency [15].

Most Rh(D)-negative phenotype prevalence estimates were obtained from a prior study [13]; when the relevant information was not included in that study, prevalence estimates were obtained from the study by Flegr [16]. When the Rh(D)-negative prevalence for a given country was not available in either of these two studies, it was calculated as the mean of the Rh(D)-negative prevalence in neighboring countries weighted by the number of inhabitants of each.

The annual number of doses of IgG anti-Rh(D) actually administered in each country was primarily derived from two sources: a prior publication [13] and the IQVIA Multinational Integrated Data Analysis System (MIDAS). MIDAS is the most comprehensive source of information on international drug prices and sales [17]. It summarizes data obtained from IQVIA's detailed audits of pharmaceutical purchases made by retailers (in 70 countries) and hospitals (in 45 countries). MIDAS contains information on sales of individual products, measured in both currency and physical units, as well as information on the product manufacturer, the active ingredient, brand, form, strength, pack size, and therapeutic class [18]. MIDAS data have been extensively used for research purposes [17–21].

## Analysis

For each country, the following were calculated: (1) the annual number of doses of IgG anti-Rh(D) needed for post-partum immunoprophylaxis and (2) the annual number of doses of IgG anti-Rh(D) needed for antenatal immunoprophylaxis. The number of doses of IgG anti-Rh(D) required for post-partum immunoprophylaxis coincides with the number of Rh(D)-positive neonates delivered by Rh(D)-negative women; for this calculation, it was assumed that all neonates would be typed for the presence or absence of Rh(D). To this end, we calculated the annual number of pregnancies for Rh(D)-negative women by multiplying the annual number of births by the prevalence of the Rh(D)-negative phenotype. Then, we multiplied this number of pregnancies in Rh(D)-negative women by the prevalence of the Rh(D) allele, which represents the probability of having the neonate inherit an Rh(D) allele from the father. The prevalence of the Rh(D) allele was calculated as complementary to the prevalence of the Rh(D)-negative allele; the latter, in turn, due to its recessive inheritance, was calculated as the square root of the prevalence of Rh(D)-negative phenotype. An equivalent methodology has been used previously [11, 13].

The annual number of doses of IgG anti-Rh(D) required for antenatal immunoprophylaxis coincides with the annual number of pregnancies involving an Rh(D)-negative woman and an Rh(D)-positive man; in this case, it was assumed that antenatal prophylaxis would be provided without knowing the Rh(D) status of the fetus. Therefore, the number of doses was calculated by multiplying the number of pregnancies in Rh(D)-negative women by the prevalence of the Rh(D)-positive phenotype. The prevalence of the Rh(D)-positive genotype was calculated as complementary to Rh(D)-negative phenotype prevalence. Nonetheless, there are a few high income countries (e.g., Denmark and the Netherlands) who have national programs to perform antenatal cell-free DNA testing for Rh(D) using maternal plasma [1,2]; in these cases our approach overestimates the number of doses required for antenatal (but not postnatal) immunoprophylaxis.

The annual number of doses of IgG anti-Rh(D) required for post-partum immunoprophylaxis and the sum of the doses of IgG anti-Rh(D) required for both postpartum and antenatal

immunoprophylaxis, respectively, set the minimum and optimum annual thresholds for preventing maternal sensitization to the Rh(D) antigen resulting from pregnancy.

To have a global overview regarding the status of immunoprophylaxis required to prevent sensitization to the Rh(D) antigen, the country-level estimates of the annual number of antenatal and post-partum doses of IgG anti-Rh(D) required, and of the annual number of doses of IgG anti-Rh(D) administered, were grouped by Global Burden of Disease (GBD) Super Region. GBD Super Region grouping is based not only on geographic location, but also on a country's Gross Domestic Product (GDP) [13]. In particular, countries were grouped into the following 7 GBD Super Regions: High Income, Asia East, South East and Pacific, Eastern Europe/Central Asia, North Africa/Middle East, Latin America and Caribbean, Sub-Saharan Africa, and Asia South; [S1 Appendix](#) lists the countries included in each GBD Super Region. All GBD Super Region estimates, along with the differences between the number of doses of IgG anti-Rh(D) required for post-partum immunoprophylaxis and the number of doses of IgG anti-Rh(D) administered (i.e.,  $\Delta$ ), were calculated. Then, for each GBD Super Region, the number of anti-D IgG doses administered were graphically compared to the minimum and optimum thresholds for preventing maternal sensitization to the Rh(D) antigen. Because data concerning the number of doses actually administered were available for some countries [13, 17], but not for others, we adopted a conservative approach in estimating the number of doses administered worldwide, in an effort to be conservative by minimizing the "gap." In particular, for countries with data available from both Ref. [13] and [17], we used the source reporting the highest number of doses administered; for countries with no available information, we took the most conservative approach by assuming that the annual number of doses administered actually equaled the annual number of doses required for both antenatal and post-partum immunoprophylaxis.

Finally, to quantify the "gap" in a way that would allow comparisons between countries, we calculated the proportion of the doses of IgG anti-Rh(D) not administered divided by what should have been administered to prevent sensitization of Rh(D)-negative women delivering an Rh(D)-positive baby (i.e., if only post-partum immunoprophylaxis were provided) using the following formula:

$$\text{Gap} = \left[ 1 - \frac{\text{anti-Rh(D) IgG doses administered}}{\text{anti-Rh(D) IgG doses required to provide post-partum immunoprophylaxis}} \right] \times 100$$

The calculated gaps were then plotted onto a worldwide heat-map. For this analysis, no assumptions were made for countries where information about anti-Rh(D) immunoprophylaxis was not available; these countries are presented in white on the heat-map. As in the GBD Super Region analysis above, for countries where the information about the number of doses of IgG anti-Rh(D) administered was available from both Ref. [13] and [17], the source reporting the highest number of such doses was used to provide the most conservative estimates.

## Results

The annual number of doses of IgG anti-Rh(D) required to provide antenatal and post-partum immunoprophylaxis by GBD Super Region is shown in [Table 1](#), together with the total number of annual doses actually administered and the difference between the number of IgG anti-Rh(D) doses required for post-partum immunoprophylaxis and the number actually administered (i.e.,  $\Delta$ ). Focusing on these worldwide estimates, a total of ~13 million annual doses are required globally to prevent sensitization to Rh(D) (i.e., by providing immunoprophylaxis both antenatally and post-partum). However, fewer than 4 million doses are currently administered annually; this outcome does not even achieve the minimum threshold for preventing


**Table 1. The number of anti-Rh(D) doses required annually to prevent maternal sensitization to Rh(D), and the number of anti-Rh(D) doses actually administered annually.**

Super GBD Region	Antenatal Doses Needed	Post-partum Doses Needed	Total Doses Needed	Total Doses Administered	$\Delta$
High Income	1,283,343	924,928	2,208,271	1,755,448	-
Asia East, S.East and Pacific	147,939	137,006	284,945	73,640	63,366
Asia South	1,967,810	1,577,724	3,545,534	394,756	1,182,968
Eastern Europe/ Central Asia	616,632	450,982	1,067,614	245,827	205,155
Latin America and Caribbean	896,050	673,265	1,569,315	365,404	307,861
North Africa/Middle East	991,502	751,921	1,743,423	665,683	86,238
Sub-Saharan Africa	1,387,024	1,152,257	2,539,281	110,922	1,041,335
<b>World</b>	<b>7,290,300</b>	<b>5,668,083</b>	<b>12,958,383</b>	<b>3,611,680</b>	<b>2,886,923</b>

<https://doi.org/10.1371/journal.pone.0235807.t001>

Rh(D) sensitization by providing only post-partum immunoprophylaxis, which would require more than 5 million doses annually. Finally, more than 2.5 million additional annual doses of IgG anti-Rh(D) are needed outside of the high income countries to achieve post-partum immunoprophylaxis alone ( $\Delta$ ; Table 1).

As shown in Fig 1, the “High Income” GBD Super Region is the only one for which the total number of annual doses of IgG anti-Rh(D) administered falls inside the green “acceptability area;” this is, the area between the minimum (i.e., post-partum prophylaxis only) and optimum (i.e., both antepartum and post-partum prophylaxis) thresholds for anti-Rh(D) immunoprophylaxis. For all the other GBD Super Regions, the total number of doses administered falls well below the minimum threshold; Asia South and Sub-Saharan Africa are the GBD Super Regions furthest from the acceptability area (by more than 1 million doses each). The number of doses needed to reach the acceptability area is ~300,000 for the Latin America and Caribbean Super Region and ~200,000 for Eastern Europe/Central Asia Super Region,



**Fig 1. IgG anti-Rh(D) doses actually administered annually, as compared with minimum and optimum thresholds for immunoprophylaxis.** The GBD Super Regions are indicated along the x-axis and the annual number of doses of IgG anti-Rh(D) are indicated along the y-axis. The annual numbers of IgG anti-Rh(D) doses actually administered in each GBD Super Region are indicated by filled-in black diamonds. The minimum threshold number of annual IgG anti-Rh(D) doses (i.e., the number required to provide post-partum immunoprophylaxis only) is indicated by the blue line; the optimum threshold number of annual IgG anti-Rh(D) doses (i.e., the number required to provide both antenatal and post-partum immunoprophylaxis only) is indicated by the green line. The “acceptability area” is indicated in light green.


<https://doi.org/10.1371/journal.pone.0235807.g001>

whereas the North Africa/Middle East, and Asia East, S. East and Pacific Super Regions are ~90,000 and ~60,000 doses below the minimum threshold, respectively.

The heat-map in Fig 2 provides a country-by-country comparison of the proportion of annual IgG anti-Rh(D) doses not administered to those that should have been administered to provide complete post-partum immunoprophylaxis; dark green represents countries with the highest coverage, dark red with the least (S2 Appendix provides a detailed list of each country by the size of the gap and the identify of the GBD Super Region). Although these types of data were available for all countries in the Asia South Super Region, they were not available for 27 countries (indicated in white on the map): 16 of these are High Income countries; 3 each in the Asia East, S.East and Pacific, Latin America and Caribbean, and North Africa/Middle East Super Regions, and one each in the Eastern Europe/Central Asia and Sub-Saharan Super Regions.

In particular, at the extremes, we found:

- 33 countries (17%) for which post-partum immunoprophylaxis is virtually fully satisfied (dark green), of which:
  - 15 are High Income countries, representing 43% of that GBD Super Region;
  - 6 are Asia East, S.East and Pacific countries, representing 20% of that GBD Super Region;
  - 6 are Eastern Europe/Central Asia countries, representing 20% of that GBD Super Region;
  - 4 are North Africa/Middle East countries, representing 21% of that GBD Super Region.
  - 2 are Latin America and Caribbean countries, representing 6% of that GBD Super Region;
  - No countries are in the Asia South and Sub-Saharan GBD Super Regions



**Fig 2. Heat-map representing each country's gap in providing post-partum Rh(D) immunoprophylaxis.** The “gap” is the proportion of annual doses of IgG anti-Rh(D) not administered post-partum divided by those that should have been administered to prevent maternal Rh(D) sensitization. The size of the gap is indicated by various colors; dark green: fully satisfied; light green: gap between 0 and 30%; yellow: gap between 30 and 50%; light orange: gap between 50 and 80%; dark orange: gap greater than 80%; white: data not available because statistics are not tracked in these countries; gray: IgG anti-Rh(D) provided through a national volunteer program [22] and, therefore, not tracked in the MIDAS database.

<https://doi.org/10.1371/journal.pone.0235807.g002>

- 100 countries (50%) with a gap between post-partum immunoprophylaxis supply and demand higher than 80% (dark red), of which:
  - 19 are Asia East, S.East and Pacific countries, representing 63% of that GBD Super Region;
  - 5 are Asia South countries, representing 83% of that GBD Super Region;
  - 16 are Eastern Europe/Central Asia countries, representing 53% of that GBD Super Region;
  - 22 are Latin America and Caribbean countries, representing 71% of that GBD Super Region;
  - 5 are North Africa/Middle East countries, representing 26% of that GBD Super Region;
  - 33 are Sub-Saharan countries, representing 70% of that GBD Super Region.

## Discussion

Although a method to prevent maternal Rh(D) sensitization in Rh(D)-negative women and, thereby, prevent Rh(D)-disease, was discovered more than 50 years ago, the findings of the current study are tragically surprising and disappointing. They show that (1) worldwide efforts to prevent Rh(D)-negative sensitization are below the minimum threshold and far from the optimum goal, (2) the gap between IgG anti-Rh(D) supply and demand is large in low income countries, and (3) in high income countries, immunoprophylaxis for maternal Rh(D) sensitization also falls below the optimum threshold required to guarantee complete prevention.

Worldwide, the annual “gap” is more than 2.5 million doses below even the minimum threshold for Rh(D) immunoprophylaxis recommended by the WHO [23]. Although previous studies attempted to identify the burden of HDFN due to a lack of immunoprophylaxis in low income countries [11, 13] to our knowledge, this is the first study to estimate the difference between the annual number of doses of IgG anti-Rh(D) required and those administered at a global level. The enormous lack of prevention identified in the current study should be regarded as a global emergency due to a lack of maternal accessibility to IgG anti-Rh(D). As such, cooperation between health authorities, the pharmaceutical industry, and the relevant healthcare providers (e.g., physicians, nurses, midwives) is urgently needed to monitor the ongoing status of this worldwide gap and to guarantee access to, at least, post-partum immunoprophylaxis for all Rh(D)-negative women who deliver an Rh(D)-positive baby.

In addition, no GBD Super Region, including the High Income one, was found to have an acceptable level of immunoprophylaxis. The GBD Super Regions with the highest gap in absolute numbers are Asia South and Sub-Saharan Africa. Consistent with these findings, a prior study reported that Asia South and Sub-Saharan Africa are the two regions with the highest incidence of neonatal death due to kernicterus, of which Rh disease is etiologically relevant [13]. However, it is clear from both the current study and the prior one that the situation is also alarming in other GBD Super Regions.

Another important finding of this study is that, despite the common practice of post-partum immunoprophylaxis in High Income countries, it seems that antenatal immunoprophylaxis is not as widespread as recommended. Previous studies attempting to identify the global burden of Rh(D)-disease due to the failure in preventing Rh(D) sensitization often assumed that Rh(D) disease had been virtually eliminated in High Income countries by IgG anti-Rh(D) immunoprophylaxis given both antenatally and post-partum [3, 4, 7, 9, 12]. However, although the current study estimated that more than 2 million doses of IgG anti-Rh(D) should

be administered annually in High Income countries to provide both antenatal and post-partum immunoprophylaxis, we found that only ~1.7 million doses were actually administered annually. Nonetheless, it is possible that this difference is somewhat overestimated, because some High Income countries use non-invasive fetal Rh(D) genotyping programs to limit antenatal immunoprophylaxis to cases where the fetus is genotyped as Rh(D)-positive [24].

The reasons for the continuing burden of Rh disease vary widely, but discussions with representatives from many countries identified some important factors [25]. For example, in Africa, ABO and Rh blood group typing is not routinely performed in many regions, and the cost of IgG anti-Rh(D) may be 4–8 times higher than in high income countries, primarily due to the privatization of pharmacies. In addition, in South America there are often insufficient supplies of IgG anti-Rh(D), whereas in China, IgG anti-Rh(D) immunoglobulin is simply not available. In Eastern Europe and Russia, the need for IgG anti-Rh(D) immunoprophylaxis is often forgotten, particularly in the settings of miscarriage, abortion, and abnormal bleeding during pregnancy. Finally, even in High Income countries some patients may not receive optimal care [26] due to inadequate education of health care providers [27, 28].

Nonetheless, the current study has several limitations. First, information about the supply of IgG anti-Rh(D) was not available for all countries. However, for High Income countries, this absence of data does not necessarily reflect a lack of implementation of post-partum immunoprophylaxis. Indeed, for most of these countries, post-partum immunoprophylaxis, at a minimum, is the standard-of-care [1, 24, 26, 29–31]. Because the remaining countries in the High Income GBD Super Region with no available information have relatively low numbers of inhabitants, we hypothesize that their demand for IgG anti-Rh(D) is supplied by neighboring countries. On the other hand, for countries in the other GBD Super Regions for which data were lacking, we believe this could, in itself, reflect poor attention towards immunoprophylaxis. Second, for 22 of the 68 countries for which we used MIDAS data to estimate the total annual number of IgG anti-Rh(D) doses administered, only data from retail distribution channels were available (i.e., for Chile, Estonia, the countries of French West Africa, Greece, Latvia, Lebanon, Morocco, Pakistan, Peru, Tunisia, United Arab Emirates); in addition, for 3 of these 68 countries, only data from hospital channels were available (Portugal, Thailand, Vietnam). Thus, it is possible that the annual number of IgG anti-Rh(D) doses given was underestimated for some of these countries. However, we think that the underestimates are balanced by conservative assumptions made for countries where data were not available. Indeed, for these countries, we assumed that the annual number of IgG anti-Rh(D) doses administered was equal to those needed to provide both antenatal and post-partum immunoprophylaxis. Third, although MIDAS data were updated in 2017 [17], the data in Ref. [13] were from 2013; thus, we cannot exclude that the situation might have changed since 2013 for some countries. Fourth, it is possible that there is some underlying dynamic that cannot be captured by MIDAS data [17]. For example, for the Netherlands, where immunoprophylaxis protocols are effectively in place [2], we found a gap in the administration of post-partum immunoprophylaxis that was higher than 80%. The reason why MIDAS did not track IgG anti-Rh(D) doses in the Netherlands is likely due to the fact that IgG anti-Rh(D) is provided through a voluntary donation program [22] and was not quantifiable using our methods; therefore, we decided to assign the gray color to the Netherlands on the heat-map in Fig 2. Fifth, our estimates of the prevalence of the Rh(D)-negative phenotype in a given country did not take into account the possibility that significant populations of ethnic minorities may have different blood type prevalences, as compared to that of the dominant population. Sixth, even when IgG anti-Rh(D) is available and can be provided, it is possible that the health practitioner does not administer it at the appropriate time. Seventh and finally, this analysis did not account for the need for IgG anti-Rh(D) immunoprophylaxis in other obstetrical settings, such as, miscarriage, abortion,



ectopic pregnancy, bleeding during pregnancy, external version in the case of breech position, abdominal trauma, amniocentesis, and the double dose of anti-Rh(D) recommended in the setting of Caesarean delivery [3, 7–10, 12, 26]. Nonetheless, we believe that the limitations described above do not markedly affect the overall global analysis and conclusions.

## Conclusion

In summary, the data presented herein identify a global crisis in which hundreds of thousands of Rh(D)-negative women are at risk for becoming sensitized to Rh(D) because of a lack of awareness about, access to, and/or availability of appropriate immunoprophylaxis. This continues to produce a heavy global burden of Rh(D) disease, characterized by fetal demise, severe neonatal anemia, neonatal hyperbilirubinemia, and kernicterus, with hearing loss and cerebral palsy as possible consequences, more than 50 years after the invention of effective measures to prevent this disease.

## Supporting information

### S1 Appendix. GBD Super Regions.

(DOCX)

### S2 Appendix. Countries identified by the IgG anti-Rh(D) post-partum immunoprophylaxis gap, arranged by GBD Super Region.

(DOCX)

## Author Contributions

**Conceptualization:** Valeria Pegoraro, Ducciocompet Urbinati.

**Data curation:** Valeria Pegoraro, Ducciocompet Urbinati.

**Formal analysis:** Valeria Pegoraro, Ducciocompet Urbinati.

**Investigation:** Valeria Pegoraro.

**Methodology:** Valeria Pegoraro, Ducciocompet Urbinati.

**Project administration:** Steven L. Spitalnik.

**Supervision:** Steven L. Spitalnik.

**Validation:** Gerard H. A. Visser, Gian Carlo Di Renzo, Alvin Zipursky, Brie A. Stotler.

**Writing – original draft:** Valeria Pegoraro, Ducciocompet Urbinati.

**Writing – review & editing:** Gerard H. A. Visser, Gian Carlo Di Renzo, Alvin Zipursky, Brie A. Stotler, Steven L. Spitalnik.

## References

1. de Haas M, Finning K, Massey E, Roberts DJ. Anti-D prophylaxis: past, present and future. *Transfusion Medicine*. 2014 Feb; 24(1):1–7. <https://doi.org/10.1111/tme.12099> PMID: 25121157
2. de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. *Vox Sanguinis*. 2015 Aug; 109(2):99–113. <https://doi.org/10.1111/vox.12265> PMID: 25899660
3. Hendrickson JE, Delaney M. Hemolytic disease of the fetus and newborn: modern practice and future investigations. *Transfusion Medicine Reviews*. 2016 Oct 1; 30(4):159–64. <https://doi.org/10.1016/j.tmr.2016.05.008> PMID: 27397673

4. Liumbruno GM, D'Alessandro A, Rea F, Piccinini V, L Catalano, G Calizzani, et al. The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh (D) alloimmunisation. *Blood Transfusion*. 2010 Jan; 8(1):8–16. <https://doi.org/10.2450/2009.0108-09> PMID: 20104273
5. Pollack W, Gorman JG, Freda VJ, Ascari WQ, Allen AE, Baker WJ. Results of clinical trials of RhoGAM in women. *Transfusion* 1968 May–Jun; 9(3):151–3.
6. Zipursky A, Hull A, White FD, Israels LG. Foetal erythrocytes in the maternal circulation. *The Lancet*. 1959 Feb 28; 273(7070):451–2.
7. Bennardello F, Coluzzi S, Curciarello G, Todros T, Villa S. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. *Blood Transfusion*. 2015 Jan; 13(1):109–34. <https://doi.org/10.2450/2014.0119-14> PMID: 25633877
8. American College of Obstetricians and Gynecologists. ACOG practice bulletin No. 181: Prevention of Rh D alloimmunization. Clinical management guidelines for obstetrician-gynecologists. *Obstetrics & Gynecology*. 2017; 130(2):e57–70.
9. Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. *Transfusion Medicine*. 2014 Feb; 24(1):8–20. <https://doi.org/10.1111/tme.12091> PMID: 25121158
10. Sperling JD, Dahlke JD, Sutton D, Gonzalez JM, Chauhan SP. Prevention of RhD alloimmunization: a comparison of four national guidelines. *American Journal of Perinatology*. 2018 Jan; 35(02):110–9.
11. Zipursky A, Paul VK. The global burden of Rh disease. *Archives of Disease in Childhood-Fetal and Neonatal Edition*. 2011 Mar 1; 96(2):F84–5. <https://doi.org/10.1136/adc.2009.181172> PMID: 21037283
12. Bennardello F, Curciarello G. Survey on the prevention and incidence of haemolytic disease of the newborn in Italy. *Blood Transfusion*. 2013 Oct; 11(4):518–27. <https://doi.org/10.2450/2013.0179-12> PMID: 23867179
13. Bhutani VK, Zipursky A, Blencowe H, Khanna R, Sgro M, Ebbesen F, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. *Pediatric Research*. 2013 Dec 20; 74(S1):86–100.
14. Watkins K. A fair chance for every child. UNICEF; 2016.
15. The World Factbook. Central Intelligence Agency. <https://www.cia.gov/library/publications/the-world-factbook/>. (Accessed July 4, 2018)
16. Flegr J. Heterozygote advantage probably maintains Rhesus factor blood group polymorphism: Ecological regression study. *PLOS ONE*. 2016 Jan 26; 11(1):e0147955. <https://doi.org/10.1371/journal.pone.0147955> PMID: 26811928
17. Kyle MK, Allsbrook JS, Schulman KA. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union. *Health Services Research*. 2008 Aug; 43(4):1308–24. <https://doi.org/10.1111/j.1475-6773.2008.00838.x> PMID: 18355258
18. Hoebert JM, Mantel-Teeuwisse AK, Leufkens HG, Van Dijk L. Variability in market uptake of psychotropic medications in Europe reflects cultural diversity. *BMC Health Services Research*. 2017 Dec; 17(1):702. <https://doi.org/10.1186/s12913-017-2649-6> PMID: 29110651
19. Ciarametaro M, Abedi S, Sohn A, Ge CF, Odedara N, Dubois R. Concerns around budget impact thresholds: not all drugs are the same. *Value in Health*. 2017 Feb 1; 20(2):230–3. <https://doi.org/10.1016/j.jval.2016.11.031> PMID: 28237200
20. Wong IC, Murray ML, Camilleri-Novak D, Stephens P. Increased prescribing trends of paediatric psychotropic medications. *Archives of Disease in Childhood*. 2004 Dec 1; 89(12):1131–2. <https://doi.org/10.1136/adc.2004.050468> PMID: 15557050
21. Wong IC, Murray ML. The potential of UK clinical databases in enhancing paediatric medication research. *British Journal of Clinical Pharmacology*. 2005 Jun; 59(6):750–5. <https://doi.org/10.1111/j.1365-2125.2005.02450.x> PMID: 15948943
22. RheDQuin is used to prevent the formation of antibodies against blood type Rhesus D. <https://www.sanquin.org/products-and-services/plasma-pharmaceuticals/products-and-instructions/immunoglobulines>. (Accessed June 21, 2019).
23. WHO recommendation on antenatal anti-D immunoglobulin prophylaxis. <https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/antenatal-care/who-recommendation-antenatal-anti-d-immunoglobulin-prophylaxis>. (Accessed May 19, 2019)
24. Hyland CA, Millard GM, O'Brien H, Schoeman EM, Lopez GH, McGowan EC, et al. Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: comparative accuracy using two blood collection tube types. *Pathology*. 2017 Dec 1; 49(7):757–64. <https://doi.org/10.1016/j.pathol.2017.08.010> PMID: 29096879

25. Visser GH, Di Renzo GC, Spitalnik SL, Ayres-de-Campos D, Escobar MF, Barnea E, et al. The continuing burden of Rh disease 50 years after the introduction of anti-Rh (D) immunoglobulin prophylaxis; A call to action. *American Journal of Obstetrics & Gynecology*. 2019 May 20, in press.
26. Fyfe TM, Ritchey MJ, Taruc C, Crompton D, Galliford B, Perrin R. Appropriate provision of anti-D prophylaxis to RhD negative pregnant women: A scoping review. *BMC Pregnancy and Childbirth*. 2014 Dec; 14(1):411.
27. Yu A, Morris E, Adams R, Fung MK. Obstetrics and gynecology physician knowledge of Rh immune globulin prophylaxis. *Transfusion*. 2017 Jun; 57(6):1385–90. <https://doi.org/10.1111/trf.14125> PMID: 28419453
28. Ramsey G. Inaccurate doses of Rh immune globulin after Rh-incompatible fetomaternal hemorrhage: Survey of laboratory practice. *Archives of Pathology & Laboratory Medicine*. 2009 Mar; 133(3):465–9.
29. Pal M, Williams B. Prevalence of maternal red cell alloimmunisation: a population study from Queensland, Australia. *Pathology*. 2015 Feb 1; 47(2):151–5. <https://doi.org/10.1097/PAT.0000000000000225> PMID: 25551305
30. Teitelbaum L, Metcalfe A, Clarke G, Parboosingh JS, Wilson RD, Johnson JM. Costs and benefits of non-invasive fetal RhD determination. *Ultrasound in Obstetrics & Gynecology*. 2015 Jan; 45(1):84–8.
31. Doyle B, Quigley J, Lambert M, Crumlish J, Walsh C, McParland P, et al. A correlation between severe haemolytic disease of the fetus and newborn and maternal ABO blood group. *Transfusion Medicine*. 2014 Aug; 24(4):239–43. <https://doi.org/10.1111/tme.12132> PMID: 24975587